There are many factors that contribute to the under-recognition of excessive daytime sleepiness in obstructive sleep apnea, including the underreporting of symptoms. Further complicating this issue is the fact that even with optimized therapy, excessive daytime sleepiness may still persist in patients. So what steps can we take to address these and other barriers?
Find out in this Lessons in Sleep Science Research series, which reviews its prevalence, pathophysiology, and strategies for overcoming the challenges that are often faced when managing patients.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
In Partnership with